<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROMETHAZINE HYDROCHLORIDE- promethazine hydrochloride injection, solution </strong><br>Teva Parenteral Medicines, Inc.<br></p></div>
<h1>Promethazine <br>Hydrochloride Injection, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1f73bbca-907c-4bca-b692-441c7c36af9a"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Package Insert<br>Rx only</span></p>
</div>
<div class="Warning">
<a name="box"></a><a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">RESPIRATORY DEPRESSION</span>-<span class="Italics">Pediatrics</span></span></p>
<p><span class="Bold">Promethazine hydrochloride injection should not be used in pediatric patients less than 2 years of age because of the potential for fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Post-marketing cases of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, including fatalities, have been reported with use of promethazine in pediatric patients less than 2 years of age. Caution should be exercised when administering promethazine hydrochloride injection to pediatric patients 2 years of age and older (see WARNINGS-<span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>).</span></p>
<p><span class="Bold">SEVERE TISSUE INJURY, INCLUDING <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">GANGRENE</span></span></p>
<p><span class="Bold">Promethazine hydrochloride injection can cause severe chemical irritation and damage to tissue regardless of the route of administration. Irritation and damage can result from perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, unintentional intra-arterial injection, and intraneuronal or perineuronal infiltration. Adverse reactions include burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, and <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>. In some cases, <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>, including fasciotomy, skin graft and/or amputation have been required (see WARNINGS-Severe Tissue Injury, Including <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span>).</span></p>
<p><span class="Bold">Due to the risks of intravenous injection, the preferred route of administration of promethazine hydrochloride injection is deep intramuscular injection. Subcutaneous injection is contraindicated. See DOSAGE AND ADMINISTRATION for important notes on administration.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_8e4ee6b3-72e8-4df4-a0c5-564afdb09ab2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Promethazine hydrochloride injection, USP is a sterile, pyrogen-free solution for deep intramuscular or intravenous administration. Promethazine hydrochloride (10<span class="Italics">H</span>-Phenothiazine-10-ethanamine,<span class="Italics">N</span>,<span class="Italics">N</span>,α-trimethyl-, monohydrochloride, (±)-) is a racemic compound and has the following structural formula: </p>
<div class="Figure">
<img alt="promethazine hydrochloride structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ed16846a-b054-4625-b4e4-4a951e95c92e&amp;name=bea5e05d-c35d-4784-8b11-d10bfc331d05-01.jpg"><p class="MultiMediaCaption">C<span class="Sub">17</span>H<span class="Sub">21</span>ClN<span class="Sub">2</span>S                                    MW=320.88</p>
</div>
<p>Each mL contains promethazine hydrochloride, either 25 mg or 50 mg, edetate disodium 0.1 mg, calcium chloride 0.04 mg, sodium metabisulfite 0.25 mg and phenol 5 mg in Water for Injection. pH 4.0 to 5.5; buffered with acetic acid-sodium acetate. </p>
<p>Promethazine hydrochloride injection is a clear, colorless solution. The product is light sensitive. It should be inspected before use and discarded if either color or particulate is observed. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f34d4053-27e6-4c7f-a087-d09becb5d109"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Promethazine hydrochloride is a phenothiazine derivative which possesses antihistaminic, sedative, antimotion-sickness, antiemetic, and anticholinergic effects. Promethazine is a competitive H<span class="Sub">1</span> receptor antagonist, but does not block the release of histamine. Structural differences from the neuroleptic phenothiazines result in its relative lack (1/10 that of chlorpromazine) of dopamine antagonist properties. Clinical effects are generally apparent within 5 minutes of an intravenous injection and within 20 minutes of an intramuscular injection. Duration of action is four to six hours, although effects may persist up to 12 hours. Promethazine hydrochloride is metabolized in the liver, with the sulfoxides of promethazine and N-desmethylpromethazine being the predominant metabolites appearing in the urine. Following intravenous administration in healthy volunteers, the plasma half-life for promethazine has been reported to range from 9 to 16 hours. The mean plasma half-life for promethazine after intramuscular administration in healthy volunteers has been reported to be 9.8 ± 3.4 hours. </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_63c0fc80-b5a4-4d66-8c9f-b70c7f660204"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Promethazine hydrochloride injection is indicated for the following conditions: </p>
<ol>
<li>Amelioration of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to blood or plasma.</li>
<li>In <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled.</li>
<li>For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated.</li>
<li>For sedation and relief of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span> and to produce light sleep from which the patient can be easily aroused.</li>
<li>Active treatment of <span class="product-label-link" type="condition" conceptid="30284" conceptname="Motion sickness">motion sickness</span>.</li>
<li>Prevention and control of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with certain types of anesthesia and surgery.</li>
<li>As an adjunct to analgesics for the control of <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>.</li>
<li>Preoperative, postoperative, and obstetric (during labor) sedation.</li>
<li>Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_a5367ba9-a229-4f2f-9510-c54d5d8ed829"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_488c66d8-ed3c-4dda-aa24-4e99df547350"></a><a name="section-5.1"></a><p></p>
<h2>Children less than 2 years of age</h2>
<p class="First">Promethazine hydrochloride injection is contraindicated for use in pediatric patients less than two years of age due to the risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (see <span class="Bold">WARNINGS <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_02cd9266-73c4-4520-9412-4ee745d35d43"></a><a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Comatose</span> state</h2>
<p class="First">Promethazine hydrochloride injection is contraindicated in <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span> states. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c85de69f-cc33-4aab-9e1f-e5d0557fd93b"></a><a name="section-5.3"></a><p></p>
<h2>Intra-arterial injection</h2>
<p class="First">Under no circumstances should promethazine hydrochloride injection be given by intra-arterial injection due to the likelihood of severe <span class="product-label-link" type="condition" conceptid="4292397" conceptname="Arteriospasm">arteriospasm</span> and the possibility of resultant <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span> (see <span class="Bold">WARNINGS—Severe Tissue Injury, Including <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9e33358b-80b9-4b76-8f18-a004546f97ba"></a><a name="section-5.4"></a><p></p>
<h2>Subcutaneous injection</h2>
<p class="First">Promethazine hydrochloride injection should not be given by the subcutaneous route; because evidence of chemical irritation has been noted, and necrotic lesions have resulted following subcutaneous injection. The preferred parenteral route of administration is by deep intramuscular injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0e4eb1bd-242c-4b15-98a1-a42ca67a86e7"></a><a name="section-5.5"></a><p></p>
<h2>Idiosyncratic reaction or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span></h2>
<p class="First">Promethazine hydrochloride injection is contraindicated in patients who have demonstrated an idiosyncratic reaction or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to promethazine or other phenothiazines. </p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_2747aab4-8abf-4288-a3c0-1ab8934bfb00"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_wresp"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6a872c15-f60f-45eb-a3d1-5af4b8b944fc"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">Pediatrics</span></h3>
<p class="First"><span class="Bold">Promethazine hydrochloride injection should not be used in pediatric patients less than 2 years of age because of the potential for fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Post-marketing cases of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, including fatalities, have been reported with use of promethazine in pediatric patients less than 2 years of age. A wide range of weight-based doses of promethazine hydrochloride injection have resulted in <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in these patients.</span></p>
<p><span class="Bold">Caution should be exercised when administering promethazine hydrochloride injection to pediatric patients 2 years of age and older. It is recommended that the lowest effective dose of promethazine hydrochloride injection be used in pediatric patients 2 years of age and older. Avoid concomitant administration of other drugs with respiratory depressant effects because of an association with <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and sometimes <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, in pediatric patients.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6d4bc733-dea8-4eee-9883-79e2facf2383"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold">Other</span></h3>
<p class="First">Because of the risk of potentially fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, use of promethazine hydrochloride injection in patients with compromised respiratory function or patients at risk for <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> (e.g. <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>) should be avoided.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_wsevert"></a><a name="section-6.2"></a><p></p>
<h2>Severe Tissue Injury, Including <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span></h2>
<p class="First"><span class="Bold">Promethazine hydrochloride injection can cause severe chemical irritation and damage to tissues regardless of the route of administration. Irritation and damage can result from perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, unintentional intra-arterial injection, and intraneuronal or perineuronal infiltration. Adverse event reports include burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">sensory loss</span>, palsies, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, severe spasm of distal vessels, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, and <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>. In some cases, <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>, including fasciotomy, skin graft, and/ or amputation have been required.</span></p>
<p><span class="Bold">Because of the risks of intravenous injection, the preferred route of administration of promethazine hydrochloride injection is deep intramuscular injection (see DOSAGE AND ADMINISTRATION). Subcutaneous injection is contraindicated. Due to the close proximity of arteries and veins in the areas most commonly used for intravenous injection, extreme care should be exercised to avoid perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> or unintentional intra-arterial injection as <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, severe chemical irritation, severe spasm of distal vessels, and resultant <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span> requiring amputation are likely under such circumstances. <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">Aspiration</span> of dark blood does not preclude intra-arterial needle placement because blood is discolored upon contact with promethazine hydrochloride injection. Use of syringes with rigid plungers or of small-bore needles might obscure typical arterial backflow if this is relied upon alone.</span></p>
<p><span class="Bold">In the event that a patient complains of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> during intravenous injection of promethazine hydrochloride injection, the injection should be stopped immediately to evaluate for possible arterial injection or perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>.</span></p>
<p><span class="Bold">There is no proven successful management of unintentional intra-arterial injection or perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> after it occurs. Sympathetic block and heparinization have been employed during the acute management of unintentional intraarterial injection, because of the results of animal experiments with other arteriolar irritants.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_wcns"></a><a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS Depression</span></h2>
<p class="First">Promethazine hydrochloride injection may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a vehicle or operating machinery. </p>
<p>The impairment may be amplified by concomitant use of other central-nervous-system depressants such as alcohol, sedative/hypnotics (including barbiturates), general anesthetics, narcotics, narcotic analgesics, tricyclic antidepressants, and tranquilizers; therefore such agents should either be eliminated or given in reduced dosage in the presence of promethazine hydrochloride (see <span class="Bold">PRECAUTIONS—Information for Patients and Drug Interactions</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b770cf9-3886-49ce-931a-939b8b9d6f59"></a><a name="section-6.4"></a><p></p>
<h2>Lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Threshold</h2>
<p class="First">Promethazine hydrochloride injection may lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold and should be used with caution in persons with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders or in persons who are using concomitant medications, such as narcotics or local anesthetics, which may also affect <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_79011f07-fcc6-4a2a-98e5-f869c3aa0688"></a><a name="section-6.5"></a><p></p>
<h2>Bone-<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Marrow Depression</span></h2>
<p class="First">Promethazine hydrochloride injection should be used with caution in patients with bone-<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow depression</span>. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported, usually when promethazine hydrochloride has been used in association with other known marrow-toxic agents. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_wneuro"></a><a name="section-6.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></h2>
<p class="First">A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with promethazine hydrochloride alone or in combination with antipsychotic drugs. Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>). </p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span> and primary central nervous system (CNS) pathology. </p>
<p>The management of NMS should include 1) immediate discontinuation of promethazine hydrochloride, antipsychotic drugs, if any, and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS. </p>
<p>Since recurrences of NMS have been reported with phenothiazines, the reintroduction of promethazine hydrochloride should be carefully considered. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_43a09d3d-bb68-40b7-80aa-0484a4655d9f"></a><a name="section-6.7"></a><p></p>
<h2>Sulfite Sensitivity</h2>
<p class="First">Promethazine hydrochloride injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> episodes, in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in nonasthmatic people.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_61eecf8d-be5c-44c5-b36f-d9772120c77a"></a><a name="section-6.8"></a><p></p>
<h2>Visual Inspection</h2>
<p class="First">This product is light sensitive and should be inspected before use and discarded if either color or particulate is observed. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3843eaec-34f0-4dc7-8f5d-530a45b846a8"></a><a name="section-6.9"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span></h2>
<p class="First">Administration of promethazine has been associated with reported <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_198023af-6578-49c1-bb2a-ffd24a4860a1"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_e8641b56-b3a3-483b-8d17-dd74dd4652d7"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Drugs having anticholinergic properties should be used with caution in patients with narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, stenosing <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, pyloroduodenal obstruction, and bladder-neck obstruction. </p>
<p>Promethazine hydrochloride injection should be used cautiously in persons with cardiovascular disease or impairment of liver function. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_info"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be advised of the risk of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, including potentially fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in children less than 2 years of age (see <span class="Bold">WARNINGS-<span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></span>).</p>
<p>Patients should be advised of the risk of severe tissue injury, including <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span> (see <span class="Bold">WARNINGS-Severe Tissue Injury, Including <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span></span>). Patients should be advised to immediately report persistent or worsening <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or burning at the injection site.</p>
<p>Promethazine hydrochloride injection may cause marked <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or impair the mental or physical abilities required for the performance of potentially hazardous tasks, such as driving a vehicle or operating machinery. Pediatric patients should be supervised to avoid potential harm in bike riding or in other hazardous activities. The concomitant use of alcohol, sedative/hypnotics (including barbiturates), general anesthetics, narcotics, narcotic analgesics, tricyclic antidepressants, and tranquilizers may enhance impairment (see <span class="Bold">WARNINGS—<span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS Depression</span></span> and <span class="Bold">PRECAUTIONS—Drug Interactions</span>).</p>
<p>Patients should be advised to report any <span class="product-label-link" type="condition" conceptid="4319906" conceptname="Dyskinesia">involuntary muscle movements</span> (see <span class="Bold">ADVERSE REACTIONS-Paradoxical Reactions</span>). </p>
<p>Patients should be advised to avoid prolonged exposure to the sun (see <span class="Bold">ADVERSE REACTIONS-Dermatologic</span>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_ID_drug"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2fd2fedf-6fbb-4948-8340-e293170af204"></a><a name="section-7.3.1"></a><p></p>
<h3>CNS Depressants</h3>
<p class="First">Promethazine hydrochloride injection may increase, prolong, or intensify the sedative action of central-nervous-system depressants, such as alcohol, sedative/hypnotics (including barbiturates), general anesthetics, narcotics, narcotic analgesics, tricyclic antidepressants, and tranquilizers; therefore, such agents should be avoided or administered in reduced dosage to patients receiving promethazine hydrochloride. When given concomitantly with promethazine hydrochloride injection, the dose of barbiturates should be reduced by at least one-half, and the dose of narcotics should be reduced by one-quarter to one-half. Dosage must be individualized. Excessive amounts of promethazine hydrochloride injection relative to a narcotic may lead to <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and motor <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> in the patient with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; these symptoms usually disappear with adequate control of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_760888c5-8b8d-48c2-8108-cdc8ec6ee66d"></a><a name="section-7.3.2"></a><p></p>
<h3>Epinephrine</h3>
<p class="First">Because of the potential for promethazine hydrochloride to reverse epinephrine's vasopressor effect, epinephrine should NOT be used to treat <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> associated with promethazine hydrochloride injection <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c3e62f3b-c027-4d38-bc9b-1da5c15e4caf"></a><a name="section-7.3.3"></a><p></p>
<h3>Anticholinergics</h3>
<p class="First">Concomitant use of other agents with anticholinergic properties should be undertaken with caution. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3e31e8f3-3719-4d88-9215-f9570e57d3f5"></a><a name="section-7.3.4"></a><p></p>
<h3>Monoamine Oxidase (MAO) Inhibitors</h3>
<p class="First">Drug interactions, including an increased incidence of extrapyramidal effects, have been reported when some MAO Inhibitors and phenothiazines are used concomitantly. This possibility should be considered with promethazine hydrochloride injection. </p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_8fa824c9-f3fa-4ac5-a78c-7a6e045f505f"></a><a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">The following laboratory tests may be affected in patients who are receiving therapy with promethazine hydrochloride injection: </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7dae4589-92f9-47dd-8489-0ff20c9aeaf3"></a><a name="section-7.4.1"></a><p></p>
<h3>Pregnancy Tests</h3>
<p class="First">Diagnostic pregnancy tests based on immunological reactions between HCG and anti-HCG may result in false-negative or false-positive interpretations. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1f0b6ed4-0ddb-4f8f-9d07-433320bfcf80"></a><a name="section-7.4.2"></a><p></p>
<h3>Glucose Tolerance Test</h3>
<p class="First">An increase in blood glucose has been reported in patients receiving promethazine hydrochloride. </p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_1a8d1674-2675-4128-8393-a2ce1ff14523"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal studies have not been performed to assess the carcinogenic potential of promethazine hydrochloride injection, nor are there other animal or human data concerning carcinogenicity, mutagenicity, or impairment of fertility. Promethazine hydrochloride injection was nonmutagenic in the <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> test system of Ames. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_46b155bb-cb4d-4082-b17d-89669adbbf01"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_ecdd731e-3406-4751-83e5-21dd2881967f"></a><a name="section-7.6.1"></a><p></p>
<h3>Teratogenic Effects—Pregnancy Category C</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_62cb2234-bae7-4dd8-9b97-35a458e57011"></a><a name="section-7.6.1.1"></a><p></p>
<p class="First">Teratogenic effects have not been demonstrated in rat-feeding studies at doses of 6.25 and 12.5 mg/kg (approximately 2.1 and 4.2 times the maximum recommended human daily dose) of promethazine hydrochloride injection. Daily doses of 25 mg/kg intraperitoneally have been found to produce fetal mortality in rats. </p>
<p>There are no adequate and well-controlled studies of promethazine hydrochloride injection in pregnant women. Because animal reproduction studies are not always predictive of human response, promethazine hydrochloride injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<p>Adequate studies to determine the action of the drug on parturition, lactation and development of the animal neonate have not been conducted. </p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_ID_nontera"></a><a name="section-7.6.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">Promethazine hydrochloride injection administered to a pregnant woman within two weeks of delivery may inhibit platelet aggregation in the newborn. </p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_c25da90c-6fa0-4d0c-9e08-0cf30d234cca"></a><a name="section-7.7"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Promethazine hydrochloride injection may be used alone or as an adjunct to narcotic analgesics during labor (see <span class="Bold">DOSAGE AND ADMINISTRATION</span>). Limited data suggest that use of promethazine hydrochloride injection during labor and delivery does not have an appreciable effect on the duration of labor or delivery and does not increase the risk of need for intervention in the newborn. The effect on later growth and development of the newborn is unknown. (See also <span class="Bold">Pregnancy—Nonteratogenic Effects</span>.) </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_035287e6-a71f-4ac5-a086-ad0a2304db31"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether promethazine hydrochloride injection is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from promethazine hydrochloride injection, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_pediatric"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Promethazine hydrochloride injection is contraindicated for use in pediatric patients less than 2 years of age because of the potential for fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. <span class="Bold">Promethazine hydrochloride injection should be used with caution in pediatric patients 2 years of age and older</span> (see <span class="Bold">WARNINGS-<span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></span>).</p>
<p>Antiemetics are not recommended for treatment of uncomplicated <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in pediatric patients, and their use should be limited to prolonged <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> of known etiology, the <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> which can occur secondary to promethazine hydrochloride injection administration may be <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> with the CNS signs of undiagnosed primary disease, e.g. <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> or Reye's syndrome. The use of promethazine hydrochloride injection should be avoided in pediatric patients whose signs and symptoms may suggest Reye's syndrome or other <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic diseases</span>.</p>
<p>Excessively large dosage of antihistamines, including promethazine hydrochloride injection, in pediatric patients may cause <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> (see <span class="Bold">OVERDOSAGE</span>). <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> have occurred with therapeutic doses and <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of promethazine hydrochloride injection in pediatric patients. In pediatric patients who are acutely ill associated with <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, there is an increased susceptibility to <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonias</span> with the use of promethazine hydrochloride injection.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_2b2f5b88-d31d-45b8-a85a-485c82f20ad9"></a><a name="section-7.10"></a><p></p>
<h2>Geriatric Use (patients approximately 60 years or older)</h2>
<p class="First">Since therapeutic requirements for sedative drugs tend to be less in geriatric patients, the dosage should be reduced for these patients. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_e2fe2e30-c954-465f-b069-038a296cbe6f"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ed301b50-7675-4363-8dc5-72ae7c8697e2"></a><a name="section-8.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First">Promethazine hydrochloride injection is contraindicated in pediatric patients less than 2 years of age, because of the potential for fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Promethazine hydrochloride injection should be used with caution in pediatric patients 2 years of age and older (see <span class="Bold">WARNINGS-<span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_severt"></a><a name="section-8.2"></a><p></p>
<h2>Severe Tissue Injury, including <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span></h2>
<p class="First">Promethazine hydrochloride injection can cause severe chemical irritation and damage to tissues regardless of the route of administration. Irritation and damage can result from perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, unintentional intra-arterial injection and intraneuronal or perineuronal infiltration. Adverse reactions include burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">sensory loss</span>, palsies, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, severe spasm of distal vessels, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, and <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>. In some cases, <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>, including fasciotomy, skin graft, and/ or amputation have been required (see <span class="Bold">WARNINGS-Severe Tissue Injury, Including <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span>;</span> and <span class="Bold">DOSAGE AND ADMINISTRATION</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_273e8407-293e-444d-a7f0-f4bd2f51a8ab"></a><a name="section-8.3"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> is the most prominent CNS effect of this drug. Sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> such as <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, and tongue protrusion; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>, excitation, <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonic</span>-like states, <span class="product-label-link" type="condition" conceptid="434889" conceptname="Dissociative disorder">hysteria</span>. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> have also been reported.</p>
<p><span class="Bold">Cardiovascular</span></p>
<p>Increased or decreased blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, faintness.</p>
<p><span class="Bold">Dermatologic</span></p>
<p><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Bold">Hematologic</span></p>
<p><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>. </p>
<p><span class="Bold">Gastrointestinal</span></p>
<p><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. </p>
<p><span class="Bold">Respiratory</span></p>
<p><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (potentially fatal) and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> (potentially fatal). (See <span class="Bold">WARNINGS—<span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></span>.)</p>
<p><span class="Bold">Other</span></p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioneurotic edema</span>. <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (potentially fatal) has also been reported. (See <span class="Bold">WARNINGS—<span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_paradox"></a><a name="section-8.4"></a><p></p>
<h2>Paradoxical Reactions</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Hyperexcitability</span> and abnormal movements have been reported in patients following a single administration of promethazine hydrochloride injection. Consideration should be given to the discontinuation of promethazine hydrochloride injection and to the use of other drugs if these reactions occur. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> behavior have also been reported in some of these patients. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_over"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Signs and symptoms of overdosage range from mild <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the central nervous system and cardiovascular system to profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. Other reported reactions include <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4259277" conceptname="Athetosis">athetosis</span>, and extensor-plantar reflexes (Babinski reflex). </p>
<p>Stimulation may be evident, especially in pediatric patients and geriatric patients. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> may rarely occur. A paradoxical-type reaction has been reported in pediatric patients receiving single doses of 75 mg to 125 mg orally, characterized by <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">hyperexcitability</span> and <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>. </p>
<p>Atropine-like signs and symptoms—<span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>; fixed, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>; <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>; etc, as well as <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, may occur. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9da0708e-9b05-4e9a-9965-225e1636141c"></a><a name="section-9.1"></a><p></p>
<h2>Treatment</h2>
<p class="First">Treatment of overdosage is essentially symptomatic and supportive. Only in cases of extreme overdosage or individual sensitivity do vital signs, including respiration, pulse, blood pressure, temperature, and EKG, need to be monitored. Attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. Diazepam may be used to control <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span> and electrolyte losses should be corrected. Note that any depressant effects of promethazine hydrochloride injection are not reversed by naloxone. </p>
<p>Avoid analeptics, which may cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. The treatment of choice for resulting <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is administration of intravenous fluids, accompanied by repositioning if indicated. In the event that vasopressors are considered for the management of severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> which does not respond to intravenous fluids and repositioning, the administration of norepinephrine or phenylephrine should be considered. EPINEPHRINE SHOULD NOT BE USED, since its use in a patient with partial adrenergic blockade may further lower the blood pressure. Extrapyramidal reactions may be treated with anticholinergic antiparkinson agents, diphenhydramine, or barbiturates. Oxygen may also be administered. Limited experience with dialysis indicates that it is not helpful. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_dosage"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_18c0af80-fae6-40ed-a0f8-640e5c33bd04"></a><a name="section-10.1"></a><p></p>
<h2>Important Notes on Administration</h2>
<p class="First">Promethazine hydrochloride injection can cause severe chemical irritation and <span class="Bold">damage to tissues regardless of the route of administration.</span> Irritation and damage can result from perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, unintentional intra-arterial injection, and intraneuronal or perineuronal infiltration (see <span class="Bold">WARNINGS-Severe Tissue Injury, Including <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span></span>).</p>
<ul>
<li><span class="Bold">The preferred parenteral route of administration for promethazine hydrochloride injection is by deep intramuscular injection.</span></li>
<li>Under no circumstances should promethazine hydrochloride injection be given by intra-arterial injection due to likelihood of severe arteriorospasm and the possibility of resultant <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span> (see <span class="Bold">WARNINGS-Severe Tissue Injury, Including <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span></span>).</li>
<li>Subcutaneous injection is contraindicated as it may result in tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>.</li>
<li>
<span class="Bold">When administered intravenously, promethazine hydrochloride injection should be given in a concentration no greater than 25 mg per mL and at a rate not to exceed 25 mg per minute.</span> It is preferable to inject through the tubing of an intravenous infusion set that is known to be functioning satisfactorily.</li>
<li>In the event that a patient complains of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> during intravenous injection of promethazine hydrochloride injection, the injection should be stopped immediately to evaluate for possible arterial injection or perivascular <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>.</li>
</ul>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
<p>Do not use promethazine hydrochloride injection if solution has developed color or contains precipitate.</p>
<p>To avoid the possibility of physical and/or chemical incompatibility, consult specialized literature before diluting with any injectable solution or combining with any other medication. Do not use if there is a precipitate or any sign of incompatibility.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fc78ccd3-52b4-4a0e-80af-e360b9c249bc"></a><a name="section-10.2"></a><p></p>
<h2>Allergic Conditions</h2>
<p class="First">The average adult dose is 25 mg. This dose may be repeated within two hours if necessary, but continued therapy, if indicated, should be via the oral route as soon as existing circumstances permit. After initiation of treatment, dosage should be adjusted to the smallest amount adequate to relieve symptoms. The average adult dose for amelioration of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to blood or plasma is 25 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3ea3bd8f-8c12-4188-ae9a-fe58c6610521"></a><a name="section-10.3"></a><p></p>
<h2>Sedation</h2>
<p class="First">In hospitalized adult patients, nighttime sedation may be achieved by a dose of 25 to 50 mg of promethazine hydrochloride injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_556b2afc-8480-414c-9ea2-b8db1855954b"></a><a name="section-10.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></h2>
<p class="First">For control of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, the usual adult dose is 12.5 to 25 mg, not to be repeated more frequently than every four hours. When used for control of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, the dosage of analgesics and barbiturates should be reduced accordingly (see <span class="Bold">PRECAUTIONS-Drug Interactions</span>). </p>
<p>Antiemetics should not be used in <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> of unknown etiology in children and adolescents (see <span class="Bold">PRECAUTIONS-Pediatric Use</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ff4adde-26af-4271-b5d8-780551a9814a"></a><a name="section-10.5"></a><p></p>
<h2>Preoperative and Postoperative Use</h2>
<p class="First">As an adjunct to preoperative or postoperative medication, 25 to 50 mg of promethazine hydrochloride injection in adults may be combined with appropriately reduced doses of analgesics and atropine-like drugs as desired. Dosage of concomitant analgesic or hypnotic medication should be reduced accordingly. (see <span class="Bold">PRECAUTIONS-Drug Interactions</span>.) </p>
<p>Promethazine hydrochloride is contraindicated for use in pediatric patients less than two years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_42b424e5-76fe-47c7-91b9-72558b7c427a"></a><a name="section-10.6"></a><p></p>
<h2>Obstetrics</h2>
<p class="First">Promethazine hydrochloride injection in doses of 50 mg will provide sedation and relieve <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span> in the early stages of labor. When labor is definitely established, 25 to 75 mg (average dose, 50 mg) promethazine hydrochloride injection may be given with an appropriately reduced dose of any desired narcotic (see <span class="Bold">PRECAUTIONS-Drug Interactions</span>). If necessary, promethazine hydrochloride injection with a reduced dose of analgesic may be repeated once or twice at four-hour intervals in the course of a normal labor. A maximum total dose of 100 mg of promethazine hydrochloride injection may be administered during a 24-hour period to patients in labor. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3d7eec54-6b90-4026-a092-c4a2c0e68891"></a><a name="section-10.7"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First"><span class="Bold">Promethazine hydrochloride injection is contraindicated for use in pediatric patients less than 2 years of age (see WARNINGS-<span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>). Caution should be exercised when administering promethazine hydrochloride injection to pediatric patients 2 years of age or older. It is recommended that the lowest effective dose of promethazine hydrochloride be used in pediatric patients 2 years of age and older and concomitant administration of other drugs with respiratory depressant effects be avoided (see WARNINGS-<span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>).</span></p>
<p>In pediatric patients 2 years of age and older, the dosage should not exceed half that of the suggested adult dose. As an adjunct to premedication, the suggested dose is 1.1 mg per kg of body weight in combination with an appropriately reduced dose of narcotic or barbiturate and the appropriate dose of an atropine-like drug. (see <span class="Bold">PRECAUTIONS-Drug Interactions</span>.)  Antiemetics should not be used in <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> of unknown etiology in pediatric patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_57442f7f-8e7a-474e-a9d8-7b5d4d8f33a3"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Promethazine hydrochloride injection, USP is available as follows: </p>
<a name="id_166c8f18-bc66-40c2-b11d-69bf6a996d63"></a><table>
<col align="left" width="35%">
<col align="left" width="25%">
<col align="left" width="40%">
<thead><tr class="Botrule First Last">
<td align="left" valign="top">NDC Number</td>
<td class="Toprule" align="left" valign="top">Strength</td>
<td align="left" valign="top">Package</td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">0703-<span class="Bold">2191-04</span>
</td>
<td class="Toprule" align="left" valign="top">25 mg/mL</td>
<td align="left" valign="top">1 mL fill in a 2 mL vial<br>25 vial per shelf tray</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">0703-<span class="Bold">2201-04</span>
</td>
<td align="left" valign="top">50 mg/mL</td>
<td align="left" valign="top">1 mL fill in a 2 mL vial<br>25 vial per shelf tray</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_007aff49-7558-4b6d-9122-bd164df937e7"></a><a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Store at room temperature 20°–25°C (68°–77°F) [See USP Controlled Room Temperature].</span></p>
<p><span class="Bold">Protect from light. Keep covered in carton until time of use.</span></p>
<p><span class="Bold">Do not use if solution has developed color or contains a precipitate.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa39a3e8-9cc2-404c-b306-06da0da9bc47"></a><a name="section-12"></a><p></p>
<p class="First">Rev. A 11/2011 <br><br>Teva Pharmaceuticals USA <br>Sellersville, PA 18960</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_744ef430-211b-43e3-8ae9-ff30c6bc07c4"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Promethazine Hydrochloride Injection, USP 25 mg/mL, 1mL Single Dose Vial x 25 Tray Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ed16846a-b054-4625-b4e4-4a951e95c92e&amp;name=bea5e05d-c35d-4784-8b11-d10bfc331d05-03.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3c2bc320-55b1-4537-971a-e1cf5462809d"></a><a name="section-13.1"></a><p></p>
<h2>Promethazine Hydrochloride Injection, USP 25 mg/mL, 1mL Single Dose Vial x 25 Tray Label Text</h2>
<p class="First"><span class="Bold">NDC 0703-2191-04                                      Rx only</span></p>
<p><span class="Bold">Promethazine<br>Hydrochloride<br>Injection, USP</span></p>
<p><span class="Bold">25 mg/mL</span></p>
<p><span class="Bold">FOR DEEP INTRAMUSCULAR<br>OR INTRAVENOUS USE</span></p>
<p>1 mL Single Dose Vials</p>
<p>25 Vials</p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_80b4aaa1-0a8a-484f-8df3-29614e893fc2"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Promethazine Hydrochloride Injection, USP 50 mg/mL, 1mL Single Dose Vial x 25 Tray Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ed16846a-b054-4625-b4e4-4a951e95c92e&amp;name=bea5e05d-c35d-4784-8b11-d10bfc331d05-02.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ab38cf3f-12bd-4dbf-a0f1-c011a06c81c7"></a><a name="section-14.1"></a><p></p>
<h2>Promethazine Hydrochloride Injection, USP 50 mg/mL, 1mL Single Dose Vial x 25 Tray Label Text</h2>
<p class="First"><span class="Bold">NDC 0703-2201-04                                       Rx only</span></p>
<p><span class="Bold">Promethazine<br>Hydrochloride<br>Injection, USP</span></p>
<p><span class="Bold">50 mg/mL</span></p>
<p><span class="Bold">FOR DEEP INTRAMUSCULAR<br>USE ONLY</span></p>
<p>1 mL Single Dose Vials</p>
<p>25 Vials</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROMETHAZINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">promethazine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0703-2191</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROMETHAZINE HYDROCHLORIDE</strong> (PROMETHAZINE) </td>
<td class="formItem">PROMETHAZINE HYDROCHLORIDE</td>
<td class="formItem">25 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM METABISULFITE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0703-2191-04</td>
<td class="formItem">25  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0703-2191-01</td>
<td class="formItem">1 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040454</td>
<td class="formItem">10/01/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROMETHAZINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">promethazine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0703-2201</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROMETHAZINE HYDROCHLORIDE</strong> (PROMETHAZINE) </td>
<td class="formItem">PROMETHAZINE HYDROCHLORIDE</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM METABISULFITE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0703-2201-04</td>
<td class="formItem">25  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0703-2201-01</td>
<td class="formItem">1 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040454</td>
<td class="formItem">10/01/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Teva Parenteral Medicines, Inc.
							(794362533)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bea5e05d-c35d-4784-8b11-d10bfc331d05</div>
<div>Set id: ed16846a-b054-4625-b4e4-4a951e95c92e</div>
<div>Version: 5</div>
<div>Effective Time: 20140218</div>
</div>
</div> <div class="DistributorName">Teva Parenteral Medicines, Inc.</div></p>
</body></html>
